Clearside Biomedical

Aging Global Population Will Boost Ocular Treatment Adoption

AnalystHighTarget

Not Invested

Community Contributor

Published

14 Aug 25

Updated

15 Dec 25

Views

n/a

AnalystHighTarget's Fair Value

n/a

-93.2%

50.7%

-93.2%

50.7%

You can edit this narrative until Dec 16 4:25 AM. Then, changes will post as Updates.

Author's Valuation

US$9098.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on 15 Dec 25

Fair value Increased 1k%

CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside

Analysts have sharply raised their price target on Clearside Biomedical to approximately 90 dollars from 6 dollars, citing a reassessment of fair value despite more conservative assumptions on revenue growth, profitability, and required returns. What's in the News Clearside Biomedical filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, listing assets of 1 to 10 million dollars and liabilities of 50 to 100 million dollars (court filing).

AnalystHighTarget Fair Value

US$90

98.8% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

63.54%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.50%

Calculation

US$545.38k

Earnings '28

1296.14x

PE Ratio '28

US$706.89m

Market Cap '28

US$706.89m

Market Cap '28

5.52m

No. shares '28

US$128.13

Share Price '28

US$128.13 Share Price '28

Discounted to 2025 @ 12.50% p.a.

US$89.99

Fair Value '25